FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200391036> ?p ?o ?g. }

• W4200391036 endingPage "S21" @default.
• W4200391036 startingPage "S20" @default.
• W4200391036 abstract "Abstract Background Several interventional Coronavirus Disease 2019 (COVID-19) studies assess outcomes at day 28, but this follow-up time can be too short, since COVID-19 often cause protracted disease. Further, data on mortality and readmissions after discharge are scarse. Methods Patients aged 18-100 years and hospitalized with COVID-19 in Eastern Denmark between March 18th, 2020 and January 12th, 2021, were followed for 91 days after admission. Patients were stratified in a first and second wave, by admissions before or after June 15th, 2020, app. when remdesivir and dexamethasone were introduced as standard of care. Sustained recovery was defined as the first date, achieving 14 consecutive days after hospital discharge without an event of readmission or death. Cumulative incidences of sustained recovery were estimated in both waves and in subgroups based on the patient’s maximum level of respiratory support in the first 14 days of admission as a proxy for disease severity. Risk factors for poor outcomes were assessed in a multivariable cox proportional hazards model. Results Overall 3,386 patients were included in the study; 1,137 and 2,249 patients were admitted in the first and second wave, respectively (Table 1). The cumulative incidence of sustained recovery at day 91 was higher in the second (0.79, 95% CI: 0.77,0.81) than in the first wave (0.72, 95% CI: 0.70, 0.75) (Fig. 1A). In both waves, those with more severe disease recovered at a slower rate (Fig. 2B). There were no differences in cumulative incidences of readmissions or deaths at day 91 after discharge between the two waves, cumulative incidence (0.20, 95% CI: 0.19,0.21) and (0.11, 95% CI: 0.09,0.12), respectively (Fig 1C, Fig 1D). Male sex, high age, cardiovascular disease, diabetes, chronic pulmonary disease, renal disease, malignancies and neurological disease were associated with lower rates of sustained recovery (Table 2). Conclusion A follow-up period of 28 days in clinical trials for COVID-19 treatments is too short, especially for patients with severe disease. Rates of adverse outcomes after hospital discharge are non-neglible. In-hospital mortality was reduced with improvements in treatment, but post discharge mortality and readmissions rates did not change significantly. Disclosures Carsten Utoft Niemann, PhD MD, Abbvie (Grant/Research Support, Advisor or Review Panel member)Astra Zeneca (Grant/Research Support, Advisor or Review Panel member, teaching)CSL Behring (Consultant)Genmab (Grant/Research Support)Gilead (Grant/Research Support)Janssen (Grant/Research Support, teaching)Novo Nordisk Foundation (Grant/Research Support)Roche (Grant/Research Support)Sunesis (Grant/Research Support)" @default.
• W4200391036 created "2021-12-31" @default.
• W4200391036 creator A5016794167 @default.
• W4200391036 creator A5027745738 @default.
• W4200391036 creator A5036034437 @default.
• W4200391036 creator A5043961176 @default.
• W4200391036 creator A5055579269 @default.
• W4200391036 creator A5057884204 @default.
• W4200391036 creator A5064654936 @default.
• W4200391036 creator A5080120008 @default.
• W4200391036 date "2021-11-01" @default.
• W4200391036 modified "2023-10-18" @default.
• W4200391036 title "29. Sustained Recovery in Patients Admitted to Hospital With COVID-19" @default.
• W4200391036 doi "https://doi.org/10.1093/ofid/ofab466.029" @default.
• W4200391036 hasPublicationYear "2021" @default.
• W4200391036 type Work @default.
• W4200391036 citedByCount "0" @default.
• W4200391036 crossrefType "journal-article" @default.
• W4200391036 hasAuthorship W4200391036A5016794167 @default.
• W4200391036 hasAuthorship W4200391036A5027745738 @default.
• W4200391036 hasAuthorship W4200391036A5036034437 @default.
• W4200391036 hasAuthorship W4200391036A5043961176 @default.
• W4200391036 hasAuthorship W4200391036A5055579269 @default.
• W4200391036 hasAuthorship W4200391036A5057884204 @default.
• W4200391036 hasAuthorship W4200391036A5064654936 @default.
• W4200391036 hasAuthorship W4200391036A5080120008 @default.
• W4200391036 hasBestOaLocation W42003910361 @default.
• W4200391036 hasConcept C120665830 @default.
• W4200391036 hasConcept C121332964 @default.
• W4200391036 hasConcept C126322002 @default.
• W4200391036 hasConcept C187212893 @default.
• W4200391036 hasConcept C194828623 @default.
• W4200391036 hasConcept C2779134260 @default.
• W4200391036 hasConcept C3008058167 @default.
• W4200391036 hasConcept C50382708 @default.
• W4200391036 hasConcept C524204448 @default.
• W4200391036 hasConcept C61511704 @default.
• W4200391036 hasConcept C71924100 @default.
• W4200391036 hasConcept C72563966 @default.
• W4200391036 hasConcept C88879693 @default.
• W4200391036 hasConceptScore W4200391036C120665830 @default.
• W4200391036 hasConceptScore W4200391036C121332964 @default.
• W4200391036 hasConceptScore W4200391036C126322002 @default.
• W4200391036 hasConceptScore W4200391036C187212893 @default.
• W4200391036 hasConceptScore W4200391036C194828623 @default.
• W4200391036 hasConceptScore W4200391036C2779134260 @default.
• W4200391036 hasConceptScore W4200391036C3008058167 @default.
• W4200391036 hasConceptScore W4200391036C50382708 @default.
• W4200391036 hasConceptScore W4200391036C524204448 @default.
• W4200391036 hasConceptScore W4200391036C61511704 @default.
• W4200391036 hasConceptScore W4200391036C71924100 @default.
• W4200391036 hasConceptScore W4200391036C72563966 @default.
• W4200391036 hasConceptScore W4200391036C88879693 @default.
• W4200391036 hasIssue "Supplement_1" @default.
• W4200391036 hasLocation W42003910361 @default.
• W4200391036 hasLocation W42003910362 @default.
• W4200391036 hasOpenAccess W4200391036 @default.
• W4200391036 hasPrimaryLocation W42003910361 @default.
• W4200391036 hasRelatedWork W1580426574 @default.
• W4200391036 hasRelatedWork W2089620537 @default.
• W4200391036 hasRelatedWork W2147263480 @default.
• W4200391036 hasRelatedWork W2275480158 @default.
• W4200391036 hasRelatedWork W2371214482 @default.
• W4200391036 hasRelatedWork W2421376569 @default.
• W4200391036 hasRelatedWork W2929987155 @default.
• W4200391036 hasRelatedWork W3095306390 @default.
• W4200391036 hasRelatedWork W4238089809 @default.
• W4200391036 hasRelatedWork W99283317 @default.
• W4200391036 hasVolume "8" @default.
• W4200391036 isParatext "false" @default.
• W4200391036 isRetracted "false" @default.
• W4200391036 workType "article" @default.